What's driving the Atrial Fibrillation Devices Market Size? Key Players are Abbott Laboratories, Johnson & Johnson, Atricure Inc., Microport Scientific Corporation and Boston Scientific Corporation. Other notable participants include St. Jude medical, Inc

Market Study Report Has Added A New Report On Atrial Fibrillation Devices Market That Provides A Comprehensive Review Of This Industry With Respect To The Driving Forces Influencing The Market Size. Comprising The Current And Future Trends Defining The Dynamics Of This Industry Vertical, This Report Also Incorporates The Regional Landscape Of Atrial Fibrillation Devices Market In Tandem With Its Competitive Terrain.

Atrial Fibrillation Devices Market will exceed USD 12.5 billion by 2025; as per a new research report.

Rise in adoption rate of enhanced technologies coupled with availability of sophisticated healthcare infrastructure will boost atrial fibrillation devices industry growth across the globe. Presence of reimbursement scenario in developed regions will further propel industry expansion. Moreover, rising prevalence of cardiovascular diseases owing to sudden transition of lifestyle and growing trends of tobacco intake in millennials will prove to be high market impact rendering factor. Continuous growth in geriatric population is another reason responsible for upward trajectory of atrial fibrillation market growth.

Request a sample of this premium report titled at: https://www.marketstudyreport.com/request-a-sample/1979116/?utm_source=openpr.com&utm_medium=ADS

Currently, high cost associated with the application of atrial fibrillation devices will act as a market restraining factor. Additionally, poor health care access in some parts of under developed regions and lack of awareness about latest technological advents are few major hindrances for the market growth.

EP ablation catheters market is forecasted to witness a lucrative CAGR of 14.4% over the forecast period. Ablation catheters are most extensively used across the globe owing to increasing preference for minimally invasive surgeries. Furthermore, adoption rate of catheter ablation system is high due to increasing success rate of paroxysmal, persistent and permanent conditions of atrial fibrillation procedures. Venture capital investment in research and development of such devices is another market augmenting factor.

Hospitals as an end-use held significant market share and was valued at around USD 2,483.4 million in the year 2018. The hospital end-use segment is dominating the atrial fibrillation devices market owing to increasing number of multi-specialty hospitals and people?s preference for hospitals over other healthcare facilities. Moreover, procedures related to atrial fibrillation are mostly performed in hospital settings. Hence, the demand for atrial fibrillation devices are highest in hospitals as compared to other healthcare facilities. Increasing number of hospitals admissions for atrial fibrillation in developed countries will strongly drive the segment growth in the coming years.

U.S atrial fibrillation devices market will witness a growth at 13.9% during the forecast period. Availability of cutting-edge technologies and rising healthcare expenditure in the U.S. will enable efficient growth of atrial fibrillation devices market. With growing popularity of these systems, more and more installations are anticipated to take place during the projection years.

China atrial fibrillation devices market was valued at around USD 324.7 million in the year 2018. The region provides lucrative growth opportunity owing to rising prevalence of cardiovascular diseases in the country. Growing healthcare expenditure of China and citizen?s financial position will propel industry growth over the forecast period.

Industry players having a strong foothold in the global market include Abbott Laboratories, Johnson & Johnson, Atricure Inc., Microport Scientific Corporation and Boston Scientific Corporation. Other notable participants include St. Jude medical, Inc., Medtronic Plc, Koninklijke Philips N.V., Siemens AG. etc. Several well-known firms are entering in sparsely addressed high potential geographies in order to expand their market presence. Innovative product launch in developing economies by these companies permits them to cater to unmet needs of the patient population and hence, expand revenue bases.

Request a discount on standard prices of this premium report titled at: https://www.marketstudyreport.com/check-for-discount/1979116/?utm_source=openpr.com&utm_medium=ADS

Report Content

Chapter 1. Methodology

1.1. Methodology

1.2. Market definition

1.3. Forecast parameters

1.4. Data sources

1.4.1. Secondary

1.4.1.1. Paid sources

1.4.1.2. Unpaid sources

1.4.2. Primary

Chapter 2. Executive Summary

2.1. Atrial fibrillation devices industry 360 degree synopsis, 2014 - 2025 (USD Million)

2.1.1. Business trends

2.1.2. Product trends

2.1.3. End-use trends

2.1.4. Regional trends

Chapter 3. Atrial Fibrillation Devices Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2014 - 2025 (USD Million)

3.3. Industry impact factors

3.3.1. Growth drivers

3.3.1.1. High adoption rate of advanced technologies and presence of sophisticated healthcare infrastructure in North America

3.3.1.2. Increase in prevalence of cardiovascular diseases in Asia Pacific region

3.3.1.3. Favorable reimbursement scenario

3.3.1.4. Rising geriatric population in Latin America

3.3.1.5. Rise in prevalence of rheumatic valvular heart diseases in Middle East and Africa

3.3.2. Industry pitfalls & challenges

3.3.2.1. High cost associated with atrial fibrillation devices

3.3.2.2. Poor health care access and suboptimal therapy in the Middle East and African region

3.3.2.3. Lack of awareness regarding enhanced medical technologies in underdeveloped and developing regions

3.4. Growth potential analysis

3.4.1. By product

3.4.2. By end-use

3.5. Regulatory landscape

3.5.1. U.S.

3.5.2. Europe

3.6. Technology landscape

3.7. Reimbursement scenario, by region and country

3.7.1. North America

3.7.1.1. U.S.

3.7.1.2. Canada

3.7.2. Europe

3.7.2.1. Austria

3.7.2.2. Belgium

3.7.2.3. Croatia

3.7.2.4. Czech Republic

3.7.2.5. Denmark

3.7.2.6. Finland

3.7.2.7. France

3.7.2.8. Germany

3.7.2.9. Greece

3.7.2.10. Hungary

3.7.2.11. Ireland

3.7.2.12. Italy

3.7.2.13. Netherlands

3.7.2.14. Norway

3.7.2.15. Portugal

3.7.2.16. Russia

3.7.2.17. Serbia

3.7.2.18. Slovakia

3.7.2.19. Spain

3.7.2.20. Sweden

3.7.2.21. Switzerland

3.7.2.22. Turkey

3.7.2.23. UK

3.7.3. Asia Pacific

3.7.3.1. India

3.7.3.2. Indonesia

3.7.3.3. Malaysia

3.7.3.4. New Zealand

3.7.3.5. Philippines

3.7.3.6. South Korea

3.7.3.7. Taiwan

3.7.3.8. Vietnam

3.8. Atrial fibrillation catheter ablation procedures, by country, 2014 - 2025

3.8.1. North America

3.8.1.1. U.S.

3.8.1.2. Canada

3.8.2. Europe

3.8.2.1. North Europe

3.8.2.1.1. UK

3.8.2.1.2. Sweden

3.8.2.1.3. Denmark

3.8.2.1.4. Norway

3.8.2.1.5. Finland

3.8.2.1.6. Estonia

3.8.2.1.7. Latvia

3.8.2.1.8. Lithuania

3.8.2.2. South Europe

3.8.2.2.1. Spain

3.8.2.2.2. Italy

3.8.2.2.3. Slovenia

3.8.2.2.4. Portugal

3.8.2.2.5. Croatia

3.8.2.2.6. Serbia

3.8.2.3. East Europe

3.8.2.3.1. Russia

3.8.2.3.2. Ukraine

3.8.2.3.3. Poland

3.8.2.3.4. Czech Republic

3.8.2.3.5. Hungary

3.8.2.3.6. Slovakia

3.8.2.3.7. Belarus

3.8.2.3.8. Bulgaria

3.8.2.3.9. Romania

3.8.2.4. West Europe

3.8.2.4.1. Germany

3.8.2.4.2. France

3.8.2.4.3. Switzerland

3.8.2.4.4. Belgium

3.8.2.4.5. Austria

3.8.2.4.6. Luxemburg

3.8.3. Asia Pacific

3.8.3.1. China

3.8.3.2. Japan

3.8.3.3. India

3.8.3.4. Australia

3.8.3.5. South Korea

3.8.3.6. Indonesia

3.8.3.7. Malaysia

3.8.3.8. New Zealand

3.8.3.9. Singapore

3.8.3.10. Taiwan

3.8.4. Latin America

3.8.4.1. Brazil

3.8.4.2. Argentina

3.8.4.3. Venezuela

3.8.4.4. Columbia

3.8.4.5. Mexico

3.8.4.6. Chile

3.8.4.7. Uruguay

3.8.5. Middle East and Africa

3.8.5.1. South Africa

3.8.5.2. Saudi Arabia

3.8.5.3. UAE

3.8.5.4. Egypt

3.9. Catheter ablation centres, by country, 2014 - 2025

3.9.1. North America

3.9.1.1. U.S.

3.9.1.2. Canada

3.9.2. Europe

3.9.2.1. North Europe

3.9.2.1.1. UK

3.9.2.1.2. Sweden

3.9.2.1.3. Denmark

3.9.2.1.4. Norway

3.9.2.1.5. Finland

3.9.2.1.6. Estonia

3.9.2.1.7. Latvia

3.9.2.1.8. Lithuania

3.9.2.2. South Europe

3.9.2.2.1. Spain

3.9.2.2.2. Italy

3.9.2.2.3. Slovenia

3.9.2.2.4. Portugal

3.9.2.2.5. Croatia

3.9.2.2.6. Serbia

3.9.2.3. East Europe

3.9.2.3.1. Russia

3.9.2.3.2. Ukraine

3.9.2.3.3. Poland

3.9.2.3.4. Czech Republic

3.9.2.3.5. Hungary

3.9.2.3.6. Slovakia

3.9.2.3.7. Belarus

3.9.2.3.8. Bulgaria

3.9.2.3.9. Romania

3.9.2.4. West Europe

3.9.2.4.1. Germany

3.9.2.4.2. France

3.9.2.4.3. Switzerland

3.9.2.4.4. Belgium

3.9.2.4.5. Austria

3.9.2.4.6. Luxemburg

3.9.3. Asia Pacific

3.9.3.1. China

3.9.3.2. Japan

3.9.3.3. India

3.9.3.4. South Korea

3.9.3.5. Indonesia

3.9.3.6. Malaysia

3.9.3.7. New Zealand

3.9.3.8. Singapore

3.9.3.9. Taiwan

3.9.4. Latin America

3.9.4.1. Brazil

3.9.4.2. Argentina

3.9.4.3. Venezuela

3.9.4.4. Columbia

3.9.4.5. Mexico

3.9.4.6. Chile

3.9.4.7. Uruguay

3.10. Global atrial fibrillation prevalence, 2017

3.11. Atrial fibrillation devices pricing analysis, by manufacturer

3.11.1. Biosense Webster (Johnson and Johnson)

3.11.2. St. Jude Medical (Abbott)

3.11.3. Boston Scientific

3.11.4. Stereotaxis

3.11.5. Medtronic

3.12. Global diagnosed cases of atrial fibrillation, 2014 - 2025

3.12.1. North America

3.12.1.1. U.S.

3.12.1.2. Canada

3.12.2. Europe

3.12.2.1. Germany

3.12.2.2. UK

3.12.2.3. France

3.12.2.4. Spain

3.12.2.5. Italy

3.12.3. Asia Pacific

3.12.3.1. China

3.12.3.2. Japan

3.12.3.3. India

3.12.3.4. Australia

3.12.3.5. South Korea

3.12.4. Rest of the World

3.13. Porter's analysis

3.14. Competitive landscape, 2017

3.14.1. Strategy dashboard

3.15. PESTEL analysis

More Details on this Report: https://www.marketstudyreport.com/reports/atrial-fibrillation-devices-market?utm_source=openpr.com&utm_medium=ADS

Contact Us:

Market Study Report LLC
4 North Main Street,
Selbyville, Delaware 19975
USA
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Web site: www.marketstudyreport.com
Blog: www.marketstudyreport.com/blog/

About Us:

Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

This release was published on openPR.